Overexpression of Ras-Related C3 Botulinum Toxin Substrate 2 Radiosensitizes Melanoma Cells <i>In Vitro</i> and <i>In Vivo</i>

Hu, Wentao; Zhu, Lin; Pei, Weiwei; Pan, Shuxian; Guo, Ziyang; Wu, Anqing; Pei, Hailong; Nie, Jing; Li, Bingyan; Furusawa, Yoshiya; Konishi, Teruaki; Hei, Tom K.; Zhou, Guangming

doi:10.1155/2019/5254798

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Melanoma, also known as malignant melanoma (MM), is a type of malignant tumour that originates from melanocytes in the basal layer of the epidermis ( 1 ). It is considered one of the most aggressive cancer diseases due to its high malignancy and treatment resistance ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Primary Malignant Melanoma of the Cervix: An Integrated Analysis of Case Reports and Series

Min¹,

Huang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Melanoma, also known as malignant melanoma, is a type of malignant tumour that originates from melanocytes in the basal layer of the epidermis. Primary malignant melanomas of the female genital tract are rare. Similarly, primary malignant melanoma of cervix, which originates from cervical melanocytes, is an extremely rare disease and the second most common type of female melanoma in women aged between 15 to 44 years worldwide. To date, primary malignant melanoma of the cervix is characterized by poor patient prognosis and little consensus exists regarding the best treatment therapy. The situation is worsened by lack of clinical studies with large samples. Notably, surgery remains the preferred treatment option for patients with primary malignant melanomas of the cervix. Current treatments are based on Federation International of Gynecology and Obstetrics(2018) staging with reference to National Comprehensive Cancer Network guidelines. This study is in order to find a more suitable treatment modality for primary malignant melanoma of cervix. Therefore, we first conducted an integrated analysis of case reports and series to assess the impact of various factors on the prognosis of such patients. In summary, this is the first pooled analysis including 149 cases of primary cervical melanoma. We found that patients who underwent radical hysterectomy-based surgery, those with non-metastatic lymph nodes and those who underwent lymphadenectomy had significantly higher survival rates. In patients who had RH-based surgery, survival rates at the 24m time point of those who did not add other treatments was higher than those who did, but for those who had total hysterectomy-based surgery, the addition of other treatments to prolong median survival may be considered. In the overall analysis, age and lymphadenectomy were associated with increased and reduced risk of death in these patients, respectively. Although there is no statistical difference, stage III&IV, TAH, lymphatic metastases increase the risk of death; whereas radical hysterectomy was associated with reduced risk of death. In the subgroup analysis, for patients who have undergone radical hysterectomy-based surgery, lymphadenectomy reduces the risk of death, while lymphatic metastases and complementary other treatments increase the risk of death. For patients who have undergone total hysterectomy-based surgery, complementary treatment reduces the risk of death. In conclusion, via summarizing previous reports, the recommended treatment procedure for PMMC are radical hysterectomy and lymphadenectomy. The addition of other treatment options for patients who undergoing RH-based surgery need further study.

show abstract

Section: Introductionmentioning

confidence: 99%

Primary Malignant Melanoma of the Cervix: An Integrated Analysis of Case Reports and Series

Min¹,

Huang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Se precisan estudios doble ciego y controlados con placebo para respaldar o refutar su eficacia. Hasta ahora la única indicación aprobada de la TBA en el dolor ha sido en la migraña crónica [25].…”

Section: Discussionunclassified

Tratamiento con toxina botulínica en pacientes oncológicos

Parra¹,

García²

2022

Medicina Estética

View full text Add to dashboard Cite

Introducción. El cáncer es una de las principales causas de morbimortalidad del mundo. El tratamiento debe ser abordado desde el punto de vista biopsicosocial. A día de hoy devolver la calidad de vida al paciente oncológico es una prioridad. La toxina botulínica se considera un fármaco seguro que puede combinarse con la radioterapia y la quimioterapia. Actualmente se está observando su utilidad a nivel nociceptivo, antiinflamatorio y postquirúrgico. El objetivo es verificar la contribución de la toxina botulínica A (TBA) al aumento de la calidad de vida e investigar su perfil de seguridad en el paciente oncológico. Material y método. Se ha efectuado una búsqueda de artículos en las principales bases de datos, desde 2002 hasta 2022, a través de términos específicos para esta revisión. Así mismo, se limitó la búsqueda empleando criterios específicos de inclusión/exclusión. Resultados. Se encontraron 58 artículos, de los que 24 se consideraron relevantes para alcanzar los objetivos propuestos. Conclusiones. La seguridad y eficacia del uso de TBA en pacientes oncológicos está avalada científicamente, mostrando un buen perfil de seguridad. No obstante, deben conocerse sus límites, interacciones e indicaciones para contribuir a la mejora de la calidad de vida en cada paciente.

show abstract

“…21 Recently, multiple studies have explored the radiosensitivity of melanoma. [22][23][24] However, there is still ample opportunity to obtain a more profound understanding of the regulatory mechanism behind the radiosensitivity of melanoma.…”

Section: Discussionmentioning

confidence: 99%

LINC01224 facilitates the proliferation and inhibits the radiosensitivity of melanoma cells through the miR‐193a‐5p/NR1D2 axis

Cui

Zheng

Lü

et al. 2021

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Melanoma is a skin cancer characterized by early metastasis and high mortality.Radiotherapy is a common treatment for melanoma in patients. Long noncoding RNAs play pivotal roles in regulating the radiosensitivity of many tumors, including melanomas. In this study, the role of LINC01224 in the radiosensitivity of melanoma cells was explored. The expression of LINC01224 in melanoma was examined by reverse transcription-quantitative polymerase chain reaction, and the results showed that LINC01224 was upregulated in melanoma tissues and cells. The effects of LINC01224 on cell proliferation and apoptosis in melanoma were assessed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT), colony formation, and flow cytometry assays. The effects of LINC01224 on the radiosensitivity of melanoma were analyzed by colony formation assay. The results implied that LINC01224 knockdown inhibited cell viability and proliferation but enhanced cell apoptosis and radiosensitivity. Luciferase reporter and RNA pull-down assays were performed to evaluate the relationships between LINC01224 and miR-193a-5p or miR-193a-5p and nuclear receptor subfamily 1 group D member 2 (NR1D2). We found that LINC01224 binds to miR-193a-5p, which directly targets NR1D2. In addition, we discovered that LINC01224 upregulated NR1D2 expression by sponging miR-193a-5p in melanoma cells. Overall, the data collected in this study suggest that LINC01224 exerts oncogenic effects in melanoma via the miR-193a-5p/NR1D2 axis.

show abstract

Overexpression of Ras-Related C3 Botulinum Toxin Substrate 2 Radiosensitizes Melanoma Cells In Vitro and In Vivo

Cited by 7 publications

References 29 publications

Primary Malignant Melanoma of the Cervix: An Integrated Analysis of Case Reports and Series

Primary Malignant Melanoma of the Cervix: An Integrated Analysis of Case Reports and Series

Tratamiento con toxina botulínica en pacientes oncológicos

LINC01224 facilitates the proliferation and inhibits the radiosensitivity of melanoma cells through the miR‐193a‐5p/NR1D2 axis

Contact Info

Product

Resources

About